Business Description
Dogwood Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US92829J2033
Share Class Description:
DWTX: Ordinary SharesTotal Employee Number:
8Description
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 91.23 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 41.3 | |||||
3-Year EPS without NRI Growth Rate | 39.5 | |||||
3-Year FCF Growth Rate | 50.5 | |||||
3-Year Book Growth Rate | -36.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 49.81 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.16 | |||||
9-Day RSI | 56.3 | |||||
14-Day RSI | 52.01 | |||||
3-1 Month Momentum % | 22.22 | |||||
6-1 Month Momentum % | -46.25 | |||||
12-1 Month Momentum % | -65.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.86 | |||||
Quick Ratio | 5.86 | |||||
Cash Ratio | 5.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -243.6 | |||||
Shareholder Yield % | -7.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -35.56 | |||||
ROA % | -30.06 | |||||
ROIC % | -35.34 | |||||
3-Year ROIIC % | -19.07 | |||||
ROC (Joel Greenblatt) % | -13823.19 | |||||
ROCE % | -31.21 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.63 | |||||
Price-to-Tangible-Book | 75.65 | |||||
EV-to-EBIT | -1.32 | |||||
EV-to-Forward-EBIT | -0.25 | |||||
EV-to-EBITDA | -1.32 | |||||
EV-to-FCF | -2.44 | |||||
| Price-to-Net-Current-Asset-Value | 151.3 | |||||
Earnings Yield (Greenblatt) % | -75.76 | |||||
FCF Yield % | -30.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DWTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dogwood Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -10.6 | ||
| Beta | 1.5283 | ||
| 3-Year Sharpe Ratio | 0.1 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 90.77 | ||
| 14-Day RSI | 52.01 | ||
| 14-Day ATR ($) | 0.122517 | ||
| 20-Day SMA ($) | 1.44915 | ||
| 12-1 Month Momentum % | -65.77 | ||
| 52-Week Range ($) | 1.28 - 9.5 | ||
| Shares Outstanding (Mil) | 33.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dogwood Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dogwood Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 100 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 15 days | ||
| General meeting for 2026 | 2026-06-16 10:00 | 1.57 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 1.86 (+11.38%) | ||
| Annual report for 2025 | 2026-03-18 | 3.22 (+3.87%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-18 | 3.22 (+3.87%) | ||
| General meeting for 2025 | 2025-11-21 10:00 | 5.95 (-1.34%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 5.56 (-3.64%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 4.85 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-08 | 4.63 (+2.43%) |
Show
Entries
Dogwood Therapeutics Inc Frequently Asked Questions
What is Dogwood Therapeutics Inc(DWTX)'s stock price today?
The current price of DWTX is $1.51. The 52 week high of DWTX is $9.50 and 52 week low is $1.28.
When is next earnings date of Dogwood Therapeutics Inc(DWTX)?
The next earnings date of Dogwood Therapeutics Inc(DWTX) is 2026-08-13 Est..
Does Dogwood Therapeutics Inc(DWTX) pay dividends? If so, how much?
Dogwood Therapeutics Inc(DWTX) does not pay dividend.
Guru Commentaries on NAS:DWTX
No articles.
Press Release
Articles on Dogwood Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers